[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Onkure Therapeutics Inc (OKUR)

Onkure Therapeutics Inc (OKUR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,062
  • Shares Outstanding, K 13,674
  • Annual Sales, $ 0 K
  • Annual Income, $ -59,520 K
  • EBIT $ -63 M
  • EBITDA $ -62 M
  • 60-Month Beta 0.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.81
  • Number of Estimates 3
  • High Estimate $-0.39
  • Low Estimate $-1.05
  • Prior Year $-1.19
  • Growth Rate Est. (year over year) +31.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.97 +19.14%
on 04/10/26
5.38 -12.08%
on 05/01/26
+0.66 (+16.22%)
since 04/01/26
3-Month
2.23 +112.11%
on 02/04/26
5.38 -12.08%
on 05/01/26
+2.09 (+79.17%)
since 01/30/26
52-Week
1.70 +178.24%
on 05/13/25
5.38 -12.08%
on 05/01/26
+2.23 (+89.20%)
since 05/01/25

Most Recent Stories

More News
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3K α pan-mutant inhibitors for breast cancer...

OKUR : 4.73 (-10.25%)
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations -- Next-generation PI3K α pan-mutant inhibitor...

OKUR : 4.73 (-10.25%)
OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients...

OKUR : 4.73 (-10.25%)
OnKure Therapeutics to Participate in Upcoming Investor Conferences

BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced...

OKUR : 4.73 (-10.25%)
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

-- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 ...

OKUR : 4.73 (-10.25%)
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

OKUR : 4.73 (-10.25%)
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

OKUR : 4.73 (-10.25%)
OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

OKUR : 4.73 (-10.25%)
OnKure Therapeutics Reports Positive Preliminary Safety and Efficacy Data for OKI-219 in First-in-Human Trial

OKI-219 shows promising safety, tolerability, and pharmacokinetics, supporting further trials with fulvestrant in breast cancer patients.Quiver AI SummaryOnKure Therapeutics announced positive preliminary...

OKUR : 4.73 (-10.25%)
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

OKUR : 4.73 (-10.25%)

Business Summary

OnKure Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of precision medicines which target biologically validated drivers of cancers. The company is currently developing OKI-219. OnKure Inc., formerly known as Reneo Pharmaceuticals Inc., is based in IRVINE,...

See More

Key Turning Points

3rd Resistance Point 5.91
2nd Resistance Point 5.64
1st Resistance Point 5.19
Last Price 4.73
1st Support Level 4.47
2nd Support Level 4.20
3rd Support Level 3.75

See More

52-Week High 5.38
Last Price 4.73
Fibonacci 61.8% 3.97
Fibonacci 50% 3.54
Fibonacci 38.2% 3.11
52-Week Low 1.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.